We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
Read MoreHide Full Article
BioSig Technologies (BSGM - Free Report) , a renowned medical device company specializing in intracardiac signal visualization, has announced a significant step forward in the research and development of its artificial intelligence (AI) medical device platform. The company has entered into a collaboration with its technical advisory partner Reified Labs, based in Cambridge, MA, to drive innovation in this field.
This latest partnership will enable BioSig to deliver unmatched accuracy and precision in the field of intracardiac signal visualization.
Harnessing Integrated Healthcare Datasets
BioSig's AI medical device platform will be built upon integrated healthcare datasets. These datasets begin with extensive electrocardiogram and IECG data obtained through the company's PURE EP Platform. By leveraging this vast dataset, BioSig aims to develop a foundational machine learning (ML) model that will enhance the accuracy and efficacy of medical device technology.
More on the Collaboration
Reified Labs is a provider of advanced technical advisory services focused on artificial intelligence within the life sciences industry. Led by Dr. Alexander D. Wissner-Gross, a distinguished computer scientist, physicist, entrepreneur, and author with Harvard and MIT training, Reified Labs brings its huge expertise to the collaboration.
Image Source: Zacks Investment Research
The latest deal follows BioSig and Reified Labs’ collaboration in 2019, which resulted in multiple patent applications and a research publication on AI-enhanced electrocardiogram lead placement mapping.
Dr. Wissner-Gross recently delivered a keynote address titled "Unsupervised Medicine: The Next Wave of AI in Healthcare." The speech highlighted the huge progress made in unsupervised machine learning models, with a particular focus on artificial general intelligence (AGI).
Through the collaboration with BioSig, Dr. Wissner-Gross showcased the potential of AGI in revolutionizing healthcare. This revolutionary approach to AI in the medical field has accelerated the expected arrival date of AGI from 2043 to 2026 in just the past two years.
A Promising Future
The collaboration between BioSig and Reified Labs is paving the way for groundbreaking advancements and improved patient outcomes in the field of electrophysiology. As it applies AGI and digital signal processing to analyze signals from the human “electrome" encompassing all electrical and ionic currents in the body, the potential for medical breakthroughs related to peripheral nervous system disorders is vast.
Market Prospects
Going by the Acumen Research and Consulting report, the global electrophysiology devices market is expected to witness substantial growth. It is projected to reach $17.6 billion by 2032, representing a CAGR of 10.9% between 2023 and 2032.
The integration of AI and ML in electrophysiology devices is a major driving force behind this growth, offering opportunities for improved diagnostics, enhanced procedural efficiency and personalized treatment options. As technology continues to advance, the field of electrophysiology is poised for further transformation, revolutionizing the way cardiac conditions are diagnosed and treated, and ultimately improving the lives of patients worldwide.
Share Price Performance
Over the past year, shares of BioSig have improved 82.4% compared with the industry’s rise of 12.4%.
Penumbra’s stock has surged 164.5% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 28% in the past year against the industry’s 20.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS for 2023 have increased from $3.55 to $3.56 in the past 30 days. Shares of the company have surged 28.9% in the past year against the industry’s 20.8% decline.
HAE’s earnings beat estimates in all of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.2%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
BioSig Technologies (BSGM - Free Report) , a renowned medical device company specializing in intracardiac signal visualization, has announced a significant step forward in the research and development of its artificial intelligence (AI) medical device platform. The company has entered into a collaboration with its technical advisory partner Reified Labs, based in Cambridge, MA, to drive innovation in this field.
This latest partnership will enable BioSig to deliver unmatched accuracy and precision in the field of intracardiac signal visualization.
Harnessing Integrated Healthcare Datasets
BioSig's AI medical device platform will be built upon integrated healthcare datasets. These datasets begin with extensive electrocardiogram and IECG data obtained through the company's PURE EP Platform. By leveraging this vast dataset, BioSig aims to develop a foundational machine learning (ML) model that will enhance the accuracy and efficacy of medical device technology.
More on the Collaboration
Reified Labs is a provider of advanced technical advisory services focused on artificial intelligence within the life sciences industry. Led by Dr. Alexander D. Wissner-Gross, a distinguished computer scientist, physicist, entrepreneur, and author with Harvard and MIT training, Reified Labs brings its huge expertise to the collaboration.
Image Source: Zacks Investment Research
The latest deal follows BioSig and Reified Labs’ collaboration in 2019, which resulted in multiple patent applications and a research publication on AI-enhanced electrocardiogram lead placement mapping.
Dr. Wissner-Gross recently delivered a keynote address titled "Unsupervised Medicine: The Next Wave of AI in Healthcare." The speech highlighted the huge progress made in unsupervised machine learning models, with a particular focus on artificial general intelligence (AGI).
Through the collaboration with BioSig, Dr. Wissner-Gross showcased the potential of AGI in revolutionizing healthcare. This revolutionary approach to AI in the medical field has accelerated the expected arrival date of AGI from 2043 to 2026 in just the past two years.
A Promising Future
The collaboration between BioSig and Reified Labs is paving the way for groundbreaking advancements and improved patient outcomes in the field of electrophysiology. As it applies AGI and digital signal processing to analyze signals from the human “electrome" encompassing all electrical and ionic currents in the body, the potential for medical breakthroughs related to peripheral nervous system disorders is vast.
Market Prospects
Going by the Acumen Research and Consulting report, the global electrophysiology devices market is expected to witness substantial growth. It is projected to reach $17.6 billion by 2032, representing a CAGR of 10.9% between 2023 and 2032.
The integration of AI and ML in electrophysiology devices is a major driving force behind this growth, offering opportunities for improved diagnostics, enhanced procedural efficiency and personalized treatment options. As technology continues to advance, the field of electrophysiology is poised for further transformation, revolutionizing the way cardiac conditions are diagnosed and treated, and ultimately improving the lives of patients worldwide.
Share Price Performance
Over the past year, shares of BioSig have improved 82.4% compared with the industry’s rise of 12.4%.
Zacks Rank and Key Picks
BioSig currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the overall healthcare sector are Penumbra (PEN - Free Report) , Lantheus (LNTH - Free Report) and Haemonetics (HAE - Free Report) . Penumbra, Lantheus and Haemonetics each sport a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has surged 164.5% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 28% in the past year against the industry’s 20.8% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS for 2023 have increased from $3.55 to $3.56 in the past 30 days. Shares of the company have surged 28.9% in the past year against the industry’s 20.8% decline.
HAE’s earnings beat estimates in all of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.2%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.